News
16h
Zacks Investment Research on MSNIs Novo Nordisk Increasing Dosage to Defend Wegovy's Edge in Obesity?Novo Nordisk NVO announced that it has submitted a regulatory application to the European Medicines Agency (EMA) seeking ...
The high dose of Wegovy is one part of Novo Nordisk's plan to defend its obesity business, along with a major ...
Denmark's Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European ...
1h
Asianet Newsable on MSNHims & Hers Announces Plans To Expand Into Canada As Novo Nordisk’s Weight Loss Drug Patent ExpiresThe telehealth company stated that its entry to Canada will come as generic Semaglutide hits the market for the first time.
Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's ...
Novo Nordisk submits a higher 7.2 mg dose of Wegovy for EMA approval, backed by trials showing 21% weight loss in obesity and ...
Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...
Novo Nordisk seeks EMA approval for 7.2 mg Wegovy dose after trials show 21% weight loss in people with obesity and type 2 diabetes.
The pharmaceutical giant said WeightWatchers will work with CenterWell Pharmacy to fulfill and deliver Wegovy prescriptions.
The partnership helps Novo capture patients who have been using compounded versions of the medicine, while allowing ...
Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...
Novo Nordisk cut ties with Hims & Hers, accusing the telehealth firm of promoting Wegovy copycat versions of the weight-loss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results